| Literature DB >> 22073364 |
D Fanni1, S Nemolato, R Ganga, G Senes, C Gerosa, P Van Eyken, K Geboes, G Faa.
Abstract
The differential diagnosis between hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and metastatic colorectal adenocarcinoma (MCA) may be difficult when only based on morphology. For this purpose immunohistochemical analyses are often required, utilizing antibodies directed against CK8-18, Hep-Par1, glypican 3, CK7, CK19, CK20. Here we report a case of a 65-year-old man who presented with a clinical picture of decompensated cirrhosis. Ultrasonography revealed two nodular areas in the right liver lobe. Liver needle biopsy revealed micro-macronodular cirrhosis associated with HCC with trabecular and pseudoglandular patterns. Immunohistochemically, tumour cells were diffusely positive for CK8-18 and also diffusely immunostained by glypican 3 and Hep-Par1. Interestingly, a diffuse and strong staining for CK20 was detected in the vast majority of tumor cells, particularly in the areas showing a pseudo-glandular pattern. No immunostaining for CK7 and CK19 was found in the tumor cells. The tumor behaved aggressively, with a rapid diffusion to the whole liver. The patient died from the disease few months after presentation. These findings underline that the interpretation of the expression of CK20 alone in the differential diagnosis among HCC, CC and MCA should be done with caution because a diffuse immunoreactivity for CK20 alone may not rule out the diagnosis of HCC.Entities:
Keywords: CK20.; cholangiocarcinoma; hepatocellular carcinoma; metastatic colorectal carcinomas
Mesh:
Substances:
Year: 2009 PMID: 22073364 PMCID: PMC3167341 DOI: 10.4081/ejh.2009.e32
Source DB: PubMed Journal: Eur J Histochem ISSN: 1121-760X Impact factor: 3.188
Figure 1Hepatocellular carcinoma showing a mixed trabecular and adenoid pattern. H&E.
Figure 2Intense cytoplasmic immunoreactivity for CK20 of the majority of tumor cells.
CK7/CK20 immunostaining.
| HCC | 10% | 7% |
| Periferal CC | 96% | 47% |
| Non periferal CC | 96% | 82% |
| Colorectal carcinoma | 27% | 94% |
| Pancreatic cancer | 94% | 52% |
| Hepatoblastoma | 26% | n.a. |